Vitals Vault
LabsWhat we testTreatmentsPocketMDHow it worksGift
Log inChoose your panel

Zepbound vs Wegovy: key differences explained

Zepbound vs Wegovy differ in active drug, dosing schedule, and trial evidence. Compare benefits, risks, and access, then talk with a clinician.

Written by Vitals Vault Medical TeamMedically reviewed by Robert Lufkin, MD, Chief Medical Officer and Arti Chandra, MD, MPH, IFMCP, Board-certified in family and integrative medicine
Published October 1, 2026

Key facts

Price
Tirzepatide + B12 is $169/month (billed $169 every 4 weeks), charged only after a clinician approves it.
How it works
Answer a few health questions online. A licensed clinician reviews them. If approved, it ships to your door.
Who can get it
Adults 18 or older. A licensed clinician reviews your health history and decides whether treatment is appropriate for you. Availability depends on the state you live in.

Medically reviewed by Robert Lufkin, MD and Arti Chandra, MD, MPH, IFMCP

Ask AI for a summary
ClaudeGoogle AIGrokChatGPTPerplexity
zepbound vs wegovy medication

Table of Contents

  1. 1Side by side comparison
  2. 2Efficacy evidence
  3. 3Key differences
  4. 4Cost and access
  5. 5Side effects and warnings
  6. 6Who may choose each
  7. 7Related

Table of Contents

  1. 1Side by side comparison
  2. 2Efficacy evidence
  3. 3Key differences
  4. 4Cost and access
  5. 5Side effects and warnings
  6. 6Who may choose each
  7. 7Related

Get your $53.97 Metabolic Check free

When you start or switch your GLP-1 by Jan 31. Claim it in 2 minutes.

Zepbound (tirzepatide) and Wegovy (semaglutide) are once-weekly prescription injections FDA-approved for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. They are in the same broader GLP-1 family, but they are not the same medication. This comparison focuses on what the FDA labels and major clinical trials show, including differences in how they work, expected benefits, and key safety warnings. If you are comparing options through Vitals Vault, note that we offer compounded tirzepatide and compounded semaglutide, not the brand products.

  • Zepbound vs Wegovy: both are weekly injections for chronic weight management, but they use different active drugs.
  • Neither Zepbound nor Wegovy comes as a pill for weight loss.
  • Both can cause nausea, vomiting, and diarrhea, and both carry a boxed warning about thyroid C-cell tumors.
  • Your best choice depends on your medical history, side effects, and insurance coverage, not a single “better” option.

Get your $53.97 Metabolic Check free

When you start or switch your GLP-1 by Jan 31. Claim it in 2 minutes.

Zepbound vs Wegovy: side by side

High-level comparison based on FDA prescribing information and pivotal trials.
FeatureZepbound (tirzepatide)Wegovy (semaglutide)
Drug classDual GIP and GLP-1 receptor agonistGLP-1 receptor agonist
FDA-approved use (weight)Chronic weight management in adults with obesity or overweight plus at least one weight-related condition, with diet and exerciseChronic weight management in adults with obesity or overweight plus at least one weight-related condition, with diet and exercise
FDA-approved use (cardiovascular)Not labeled to reduce major adverse cardiovascular eventsLabeled to reduce risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight
How it is takenSubcutaneous injectionSubcutaneous injection
How oftenOnce weeklyOnce weekly
Does it come as a pill?No pill form for weight managementNo pill form for weight management
Typical trial results (context)Adults without diabetes: mean weight change at 72 weeks reported in SURMOUNT-1Adults without diabetes: mean weight change at 68 weeks reported in STEP 1

About compounded versions

Zepbound and Wegovy are brand products. Vitals Vault offers Tirzepatide (compounded, injectable) and Semaglutide (compounded, injectable) as compounded medications, not the brand products. Compounded medications are prepared by a licensed pharmacy for an individual prescription and are not FDA-approved.

What the clinical trials show

  • Tirzepatide (SURMOUNT-1)

    In adults with obesity or overweight without diabetes, SURMOUNT-1 reported mean weight reduction over 72 weeks with tirzepatide compared with placebo. The trial also reported gastrointestinal side effects and discontinuation due to adverse events. Use these results as population averages, not a prediction for you.

  • Semaglutide (STEP 1)

    In adults with obesity or overweight without diabetes, STEP 1 reported mean weight reduction over 68 weeks with semaglutide 2.4 mg compared with placebo, alongside lifestyle intervention. Gastrointestinal side effects were common and were a frequent reason for stopping treatment in the trial.

  • Cardiovascular outcomes (SELECT)

    For Wegovy, the SELECT trial evaluated semaglutide in adults with established cardiovascular disease and obesity or overweight and reported fewer major adverse cardiovascular events versus placebo. This evidence is reflected in Wegovy’s label indication for cardiovascular risk reduction in that specific population.

Key trial endpoints and timeframes (see original publications for full methods).
TrialPopulation (high level)DurationPrimary outcome (high level)
SURMOUNT-1Adults with obesity or overweight without diabetes72 weeksMean percent weight change and proportion achieving weight-loss thresholds
STEP 1Adults with obesity or overweight without diabetes68 weeksMean percent weight change and proportion achieving weight-loss thresholds
SELECTAdults with established cardiovascular disease and obesity or overweightEvent-driven, median follow-up reported in publicationMajor adverse cardiovascular events

Key differences between Wegovy and Zepbound

  • Active medication

    Zepbound contains tirzepatide, which activates two hormone pathways (GIP and GLP-1). Wegovy contains semaglutide, which activates the GLP-1 pathway. Both slow stomach emptying and reduce appetite signals, but the mechanisms are not identical.

  • Label indications beyond weight

    Wegovy’s label includes reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Zepbound’s label focuses on chronic weight management and does not include that cardiovascular risk reduction indication.

  • Dose escalation is not interchangeable

    Both medications use gradual dose escalation to improve tolerability, but the products are not dose-equivalent. If you are switching, your prescriber typically uses the product label and your side effect history rather than a simple conversion chart.

  • No pill form for either

    If you are searching for “zepbound pills” or “zepbound pill form,” Zepbound is not available as an oral tablet for weight management. Wegovy is also not an oral tablet. Oral semaglutide exists for type 2 diabetes as Rybelsus, which is a different product and indication.

Cost and access: what usually drives the difference

  • Insurance coverage varies widely

    Coverage often depends on your plan’s obesity treatment benefits, prior authorization rules, and whether you meet the label criteria (BMI and weight-related conditions). Even when covered, plans may require documentation of lifestyle efforts and follow-up.

  • Supply and pharmacy availability

    Availability can change due to manufacturing and distribution constraints. If a product is hard to find locally, your clinician may discuss alternatives that fit your medical history and access realities.

  • Monitoring and follow-up needs

    Ongoing care can include check-ins for side effects, dose adjustments, and labs when clinically indicated. These care steps can affect total out-of-pocket cost beyond the medication itself.

  • Compounded options are different products

    Compounded tirzepatide and compounded semaglutide are not the same as Zepbound or Wegovy and are not FDA-approved. If you are considering a compounded option, ask what ingredient source is used and how the pharmacy ensures quality.

Where prices appear on this page

If current prices are available, they are shown on this page in the price block. This article does not list prices because they can change.

Side effects and warnings (what matters most)

Selected risks and warnings from FDA labeling. This is not a complete list.
TopicZepbound (tirzepatide)Wegovy (semaglutide)
Common side effectsGastrointestinal effects such as nausea, vomiting, diarrhea, constipation, abdominal painGastrointestinal effects such as nausea, vomiting, diarrhea, constipation, abdominal pain
Boxed warningRisk of thyroid C-cell tumors in rodents; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2Risk of thyroid C-cell tumors in rodents; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2
Pancreatitis warningAcute pancreatitis has been reported with GLP-1 based therapies; stop and evaluate if suspected per labelAcute pancreatitis has been reported with GLP-1 based therapies; stop and evaluate if suspected per label
Gallbladder diseaseRisk of acute gallbladder disease is described in labelingRisk of acute gallbladder disease is described in labeling
Kidney riskAcute kidney injury can occur, sometimes related to dehydration from GI side effectsAcute kidney injury can occur, sometimes related to dehydration from GI side effects
Low blood sugar (hypoglycemia)Risk increases if used with insulin or insulin secretagogues; see labelRisk increases if used with insulin or insulin secretagogues; see label
  • Common: nausea and vomiting

    Nausea and vomiting are among the most common reasons people struggle with these medications, especially during dose increases. Eating smaller meals and avoiding high-fat meals may help some people, but persistent vomiting can lead to dehydration and needs clinician guidance.

  • Common: diarrhea or constipation

    Changes in bowel habits are common with both medications. If you develop severe diarrhea, cannot keep fluids down, or have symptoms of dehydration, contact a clinician promptly because dehydration can worsen kidney function.

  • Serious: pancreatitis symptoms

    Seek urgent medical care for severe abdominal pain that may radiate to the back, with or without vomiting, because this can be a sign of pancreatitis. Both products warn about acute pancreatitis and advise stopping the medication and evaluation if pancreatitis is suspected.

  • Serious: gallbladder problems

    Upper abdominal pain, fever, jaundice, or clay-colored stools can signal gallbladder disease, which is listed as a risk with GLP-1 based weight-loss medications. A clinician may evaluate for gallstones or gallbladder inflammation if symptoms occur.

  • Serious: thyroid tumor warning

    Both Zepbound and Wegovy have a boxed warning about thyroid C-cell tumors seen in rodents. They are contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

  • Serious: allergic reactions

    Stop and get emergency help for symptoms such as swelling of the face, lips, tongue, or throat, trouble breathing, or severe rash. Hypersensitivity reactions are described in labeling for both medications.

Who may choose Zepbound or Wegovy

1

Option 1

Zepbound (tirzepatide)

Potential fit

May be considered if you meet label criteria for chronic weight management and your clinician thinks a dual GIP and GLP-1 option fits your goals and tolerability.

Key considerations

  • Not the same drug as semaglutide, so side effects and response can differ.
  • Same boxed warning and key GLP-1 class warnings apply (thyroid C-cell tumors, pancreatitis, gallbladder, kidney).
  • If you have type 2 diabetes medications on board, hypoglycemia risk needs review.
2

Option 2

Wegovy (semaglutide)

Potential fit

May be considered if you meet label criteria for chronic weight management, especially if cardiovascular risk reduction labeling is relevant to your history.

Key considerations

  • Has a labeled indication to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
  • Same boxed warning and key GLP-1 class warnings apply (thyroid C-cell tumors, pancreatitis, gallbladder, kidney).
  • Not interchangeable with tirzepatide; switching should be clinician-directed.

Across all options

For either option, a clinician should review contraindications (including MTC or MEN 2), current medications, history of pancreatitis or gallbladder disease, kidney risk, pregnancy plans, and your ability to tolerate gastrointestinal side effects. Availability and insurance rules often determine what is practical.

Important safety information

Zepbound and Wegovy carry a boxed warning about thyroid C-cell tumors and are contraindicated with a personal or family history of MTC or MEN 2. Seek urgent care for severe abdominal pain (possible pancreatitis), signs of allergic reaction, or severe vomiting with dehydration. Review the full prescribing information with your clinician.

Tirzepatide + B12

Get Tirzepatide + B12 prescribed online

Not sure which fits you? Check if you qualify, then see the price.

  1. 1Answer a few health questions
  2. 2A licensed clinician reviews them
  3. 3If approved, it ships to your door

$20 to start, refunded if you don’t qualify.

Tirzepatide + B12 is $169 per 28-day supply, charged only after a clinician approves it.

Check if I qualify

Online visit with licensed US clinicians · Cancel anytime · Free shipping · Prescribed only if appropriate

  • US-licensed clinicians
  • Ships from US pharmacies
  • HSA/FSA eligible

Related treatments

Zepbound Vs MounjaroWegovy Vs OzempicZepbound Vs OzempicHow To Switch From Zepbound To WegovyIs Zepbound Better Than Wegovy

Frequently Asked Questions

Does Zepbound come in pill form?

No. Zepbound is a once-weekly subcutaneous injection, not a pill. If you want an oral option, ask a clinician which medications are appropriate for your situation and goals.

Which is better, Wegovy or Zepbound?

There is no single best choice for everyone. Trials show both can help with chronic weight management, but they use different active drugs and have different labeled indications. Your medical history, side effects, and access often decide what fits.

What is the difference between Wegovy and Zepbound?

Wegovy contains semaglutide (a GLP-1 receptor agonist) and Zepbound contains tirzepatide (a dual GIP and GLP-1 receptor agonist). Both are weekly injections with similar class warnings, but they are not dose-equivalent and are not interchangeable.

Is Wegovy the same as Zepbound?

No. They are different medications with different active ingredients and different FDA labeling details. They share some safety warnings and common gastrointestinal side effects, but they are not the same drug.

Is there a Wegovy to Zepbound dose conversion?

There is not a simple, universal conversion because the drugs are different and have different dose schedules. If you are switching, your prescriber typically uses the product labels and your tolerability and response to guide a safe transition.

4.6 out of 5

A little extra for your next check-in.

Claim a free lab test

  • Retest an eligible test from your first order
  • Use on an eligible test within six months

By claiming, you agree to receive emails from Vitals Vault. No card needed. Offer terms

Vitals Vault

For those who don’t settle for normal.

Choose your panelContact us
+1 (888) 788-5326

Sales and support · 9am-6pm PST, Mon-Fri

We fund carbon removal with Stripe Climate (opens in a new tab)

Understand Your Body

  • Biomarkers We Test
  • All Biomarkers (A–Z)
  • Explore Medications
  • Galleri® cancer screening
  • How We Analyze
  • Platform Features
  • Compare
  • Blogs

Health information

  • Signs & Symptoms
  • Learn Treatment
  • Peptide Guide
  • Improve Biomarkers
  • Conditions
  • Health Blog
  • Condition diseases

Longevity & Healthy Aging

  • Hormonal Health
  • Heart Health
  • Energy & Metabolism
  • Inflammation & Immunity
  • Vitamins & Minerals
  • Blood Health

Free Tools to Start

  • Check Your Health Score
  • Biological Age Calculator
  • Free LifeSpan Report
  • Check Lab Appointment Availability
  • Lab Locations by State

Community

  • Stories
  • Gift Health
  • For creators & affiliates
  • For clinics & practitioners
  • Partnerships
  • Developers

Support & Trust

  • Contact Us
  • About Us
  • Our Clinicians
  • FAQ

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Checkout and Intake Terms
  • Rewards terms
  • Medical Partners
  • Medical Records Authorization
  • Consumer Health Data Privacy
  • Lab Order & Information Authorization
  • Phone Number Authorization

Tests processed by CLIA-certified Quest Diagnostics labs. HSA/FSA eligible.

© 2026 Vitals Vault · Not a substitute for medical care · In an emergency, call 911